deltatrials
Completed PHASE1 INTERVENTIONAL 14-arm NCT00814229

Safety and Immunogenicity of Influenza H9 Vaccine in Humans

Randomised Dose Ranging Observer Blind Single Centre Study to Evaluate Safety and Immunogenicity of Adjuvanted and Non-adjuvanted Influenza H9 Influenza Vaccine in Humans

Sponsor: Crucell Holland BV

Conditions Influenza
Interventions H9N2 vaccine, whole virus, alum, IM, 15 microg H9N2 vaccine, whole virus, alum, IM, 45microg H9N2 virosomal vaccine, IM, 15microg H9N2 virosomal vaccine, IM, 45microg H9N2 virosomal vaccine, IM, 5microg H9N2 virosome vaccine, IM, 1.5microg H9N2 whole virus vaccine vaccine, IM, 15microg H9N2 whole virus vaccine, ID, 15microg H9N2 whole virus vaccine, ID, 5microg H9N2 whole virus vaccine, IM, 1.5microg H9N2 whole virus vaccine, IM, 45microg H9N2 whole virus vaccine, IM, 5microg H9N2 whole virus vaccine, alum, IM, 1.5microg H9N2 whole virus, alum, IM, 5microg
Updated 5 times since 2017 Last updated: Jul 20, 2009 Started: Aug 31, 2007 Primary completion: Jan 31, 2008 Completion: Sep 30, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00814229, this PHASE1 trial focuses on Influenza and remains completed. Sponsored by Crucell Holland BV, it has been updated 5 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Crucell Holland BV
  • National Institute of Biological Standards and Control
  • Public Health England
  • University Hospitals, Leicester
Data source: University Hospitals, Leicester

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations